Following protracted legal confrontations, Vanda Pharmaceuticals has agreed to withdraw or suspend multiple lawsuits against the FDA in return for re-examinations of two candidate treatments for motion disorders. This resolution may expedite regulatory reviews and clear pathways toward possible approvals, balancing industry pressures with regulatory oversight. The company's strategic pivot indicates an intensified focus on advancing pipeline assets in neurologic indications.